Real-World study checks safety of apixaban in the very elderly
NCT ID NCT04586972
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed study looked at nearly 1,000 people aged 80 and older with atrial fibrillation (an irregular heartbeat) who were newly prescribed the blood thinner apixaban. Researchers tracked bleeding events and how well the dose matched each patient's needs. The goal was to gather real-world safety data in this older group, who are often left out of drug trials.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- apixaban (a blood thinner)
- What this could lead to
- If successful, this study could help doctors better understand how to safely use apixaban in very elderly patients with atrial fibrillation.
- What could go wrong
- This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to all older adults.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
977 people
The number who actually took part.
- Started
-
Sep 2020
- Finished
-
Apr 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients newly treated with Apixaban for non-valvular atrial fibrillation (no mechanical heart valves, no known moderate or severe mitral stenosis)
- Ages
-
80 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Male or female patients aged 80 years and older. * Patients with non-valvular atrial fibrillation (documented on electrocardiography or other medical evidence like medical chart, hospital discharge note, physician's letter within 3 years before enrollment). * Followed in geriatric settings (office consultation, acute care, rehabilitation settings and nursing homes). * Newly treated (less than 6 months) with Apixaban (5mg twice daily (or 2.5 mg twice daily for patients with 2 of the following criteria : age \> 80 years, creatinine \> 133 μmol/l, weight \< 60 kg) Exclusion Criteria: * Patient refusing to participate. * Participation to a clinical trial. * Contraindication to use of Apixaban as described in the Summary of Product Characteristics .
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Nonvalvular atrial fibrillation are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Geriatric Department, Broca Hospital
Paris, IIe-de-France, 75013, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.